Skip to main content

Drug Interactions between cyclophosphamide and pentostatin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

cycloPHOSphamide pentostatin

Applies to: cyclophosphamide and pentostatin

MONITOR: Coadministration of pentostatin with cyclophosphamide may enhance the cardiotoxic effects of cyclophosphamide. The mechanism of this interaction has not been delineated. Two cases of fatal cardiovascular collapse have been reported following administration of intravenous pentostatin with high-dose oral cyclophosphamide.

MANAGEMENT: Patients receiving pentostatin and cyclophosphamide should be monitored for development of signs and symptoms of cardiotoxicity including, but not limited to respiratory distress, pulmonary edema, hypotension, hypothermia, and confusion. Some authorities recommend avoiding the use of intravenous pentostatin with high-dose oral cyclophosphamide.

References

  1. (2001) "Product Information. Cytoxan (cyclophosphamide)." Bristol-Myers Squibb
  2. (2001) "Product Information. Nipent (pentostatin)." Hospira Inc
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  4. Cerner Multum, Inc. "Australian Product Information."
View all 4 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer